ProfileGDS5678 / 1427475_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 78% 82% 79% 84% 84% 72% 82% 79% 80% 85% 83% 87% 86% 84% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.3820778
GSM967853U87-EV human glioblastoma xenograft - Control 25.99482
GSM967854U87-EV human glioblastoma xenograft - Control 35.4828879
GSM967855U87-EV human glioblastoma xenograft - Control 46.4332584
GSM967856U87-EV human glioblastoma xenograft - Control 56.2500784
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.5515572
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.7421682
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.4743879
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.7004480
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.3573585
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.0867383
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.724787
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.5812186
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 56.2320184